Neuropace Inc Stock Price, News & Analysis

NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its participation in two upcoming healthcare conferences in September 2025. The management team will attend the Wells Fargo Healthcare Conference on September 3 in Boston for one-on-one investor meetings.

Additionally, the company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4 at 9:45am ET. The fireside chat will be available via live webcast, with a replay accessible through NeuroPace's investor website.

NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, reported strong Q2 2025 financial results. The company achieved record quarterly revenue of $23.5 million, representing a 22% year-over-year growth. Gross margin improved to 77.1%, up from 73.4% in Q2 2024.

The company increased its 2025 revenue guidance to $94-98 million (18-23% growth) and raised gross margin guidance to 75-76%. Key operational highlights include preliminary data from the NAUTILUS study for IGE therapy, showing a 79% median GTC seizure reduction at 12 months. NeuroPace also secured a new $75 million credit facility with MidCap Financial and maintained favorable CMS reimbursement status for RNS procedures.

NeuroPace (Nasdaq: NPCE) announced that the Centers for Medicare & Medicaid Services (CMS) has maintained the current Medicare Severity Diagnosis Related Group (MS-DRG) assignment for RNS® System procedures under MS-DRG 023 for FY 2026. This decision comes after CMS initially proposed reassigning epilepsy with neurostimulator cases to MS-DRG 020-022.

CEO Joel Becker welcomed the decision, highlighting its importance for hospitals providing RNS System treatment to Medicare beneficiaries. The company will continue collaborating with CMS on MS-DRG improvements and reimbursement policies to ensure broader access to their epilepsy treatment technology.

NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has scheduled its second quarter 2025 financial results announcement for August 12, 2025 after market close.

The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can join via webcast or telephone, with the webcast being archived on NeuroPace's investor relations website for at least 90 days.

NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has announced a strategic CFO transition. Patrick F. Williams has been appointed as the new Chief Financial Officer effective June 20, 2025, replacing Rebecca Kuhn, who will serve in an advisory role for 12 months.

Williams brings over 25 years of financial and operational management experience in public medical device companies, having previously served as CFO at STAAR Surgical, Sientra, and ZELTIQ. The company's RNS System targets a significant market opportunity of approximately 1.2 million U.S. patients living with drug-resistant epilepsy.

NeuroPace (NPCE) has secured a new $75 million credit facility with MidCap Financial, comprising a $60 million term loan and a $15 million revolving credit facility. The financing replaces the company's existing term loan with CRG Partners IV and provides working capital for corporate purposes. The new agreement features favorable terms with reduced cash interest expense and a five-year maturity date. Interest rates are set at SOFR (minimum 2%) plus 5.5% for the term loan and 3.75% for the revolving loan. The non-dilutive capital will support NeuroPace's growth initiatives, including expanding access to their RNS System, developing new indications, implementing direct-to-consumer programs, and investing in product development and real-world evidence generation.

NeuroPace (NPCE) has announced preliminary one-year results from its NAUTILUS study evaluating the RNS® System for treating drug-resistant idiopathic generalized epilepsy (IGE). The study successfully met its primary 12-week safety endpoint, showing low serious adverse events. While the primary effectiveness endpoint didn't reach statistical significance in the overall population, a significant response was observed in a majority subgroup of patients with lower baseline seizure frequency. The study, involving 87 implanted patients across 23 US epilepsy centers, showed promising median seizure reduction rates exceeding those seen in the company's previous focal epilepsy trials. Notably, patients completing over 12 months showed continued clinical improvement. The company plans to discuss potential regulatory pathways with the FDA, including pursuing a targeted indication for patients with lower baseline seizure frequency.

NeuroPace (NPCE) reported strong Q1 2025 financial results with record quarterly revenue of $22.5 million, representing a 24% year-over-year growth. The company's RNS System revenue grew 26% year-over-year, or 29% excluding NAUTILUS study implants. Gross margin improved to 77.0%, exceeding guidance. Operating expenses increased 8% to $22.5 million, with R&D expenses rising to support product pipeline development. The company reported a net loss of $6.6 million, improved from $8.9 million in Q1 2024. NeuroPace increased its full-year 2025 revenue guidance to $93-97 million. The company's cash position strengthened to $66.3 million. Notable achievements include positive 3-year RNS System data showing 82% median seizure reduction and strategic portfolio refocusing on core RNS System products.

NeuroPace (NPCE) has provided an update regarding its exposure to implemented tariffs, stating that it expects minimal impact on its operations and financial results. The company attributes this exposure to manufacturing and selling the majority of its devices within the United States, with minimal international supply chain activities for its RNS System.

The company also expects no material impact on gross margin for DIXI Medical SEEG products and is reiterating its gross margin guidance for 2025. NeuroPace has previously announced the termination of its SEEG distribution agreement with DIXI Medical, effective October 1, 2025, followed by a six-month wind-down period through Q1 2026.

The company will report its Q1 2025 financial results on May 13, 2025, after market close, followed by a conference call at 1:30 p.m. Pacific Time.